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Since many chemotherapeutic agents can induce apoptosis in
certain cancer cells, apoptosis may play an important role in
cancer therapy (Kaufmann, 1989; Evans and Dive, 1993).
However, the molecular mechanisms of anticancer drug-induced
apoptosis are still unclear.
Several investigators have reported that activation of intra-
cellular protease is a crucial event in apoptosis (Voelkel-Johnson
et al, 1995; Wright et al, 1996). More recent studies have revealed
that, in a number of cells, apoptosis is induced by the activation of
a series of the caspase family of cysteine proteases (Fernandes-
Alnemri et al, 1994; Wang et al, 1994; Nicholson et al, 1995). It
has been reported that an inhibitor of caspase-1 or caspase-3
prevents doxorubicin (DXR)-induced apoptosis of human myeloid
leukaemia U937 cells (Yamashita et al, 1995).
It has been reported that bovine serum albumin (BSA)–DXR,
which increased cytotoxicity against several multidrug resistant
cell lines, exhibited the toxic activity after degradation of
BSA–DXR into small peptide–DXR conjugate (Takahashi et al,
1996) and that cytotoxicity of glutathione (GSH)–DXR showed
the most potent cytotoxicity against AH66 cells among DXR
coupled to several small peptides, such as glycylglycine, glycyl-
glycylglycine, GSH, oxidized glutathione and BSA (Asakura
et al, 1997a). On the other hand, our recent investigations demon-
strated that the cysteine residue of the conjugate was important for
expression of the cytotoxicity (Asakura et al, 1997a). Moreover,
we showed that GSH–DXR inhibited glutathione S-transferase
activity, but DXR did not, indicating that inhibition must be an
important contribution to the expression of potent cytotoxicity of
GSH–DXR against rat hepatoma AH66 cells (Asakura et al,
1997b). In the present study, we investigated participation of the
caspase family in the process of GSH–DXR-induced apoptosis in
rat hepatoma AH66 cells.
MATERIALS AND METHODS
Materials
DXR was obtained from Kyowa Hakko Kogyo (Tokyo, Japan).
Acetyl–Asp–Glu–Val–Asp–aldehyde (DEVD–CHO), acetyl–Tyr–
Val–Ala–Asp–aldehyde (YVAD-CHD), acetyl–Asp–Glu–Val–Asp–
a-(4-methyl-coumaryl-7-amide (DEVD-MCA), acetyl–Tyr–Val–
Ala–Asp–a-(4-methyl-coumaryl-7-amide (YVAD–MCA) and 7-
amino-4-methyl-counmarin (AMC) were purchased from Peptide
Instrument (Osaka, Japan). GSH, RNase A, proteinase K and
ethidium bromide were obtained from Sigma (St Louis, MO, USA).
Dowex 50Wx8, glutaraldehyde and agarose GP-36 were purchased
from Nakarai Tesque (Kyoto, Japan). All other chemicals were of
analytical grade.
Cell lines
Rat ascites hepatoma AH66 cells were cultured with RPMI-1640
containing 10% heat inactivated fetal bovine serum (growth
medium) under conventional conditions (Ohkawa et al, 1993;
Asakura et al, 1997a,b).
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Summary Glutathione–doxorubicin (GSH–DXR) effectively induced apoptosis in rat hepatoma cells (AH66) at a lower concentration than
DXR. After 24 h of drug treatment, DNA fragmentation of the cells was observed at the concentration of 1.0 mM DXR or 0.01 mM GSH–DXR.
Increase in caspase-3 activity and DNA fragmentation were observed within 12 h and 15 h after treatment with either drug. Intracellular
caspase-3 activity was increased in a dose-dependent manner after treatment with DXR or GSH–DXR, and caspase-3 activity correlated well
with the ability to induce DNA fragmentation. When the cells were treated with either DXR or GSH–DXR for only 6 h, apoptotic DNA
degradation and caspase-3 activation occurred 24 h after treatment. DNA fragmentation caused by these drugs was prevented completely
by simultaneous treatment with the caspase-3 inhibitor, acetyl–Asp–Glu–Val–Asp-aldehyde (DEVD-CHO), at 10 mM. By contrast, DNA
fragmentation was not prevented by the caspase-1 inhibitor, acetyl–Tyr–Val–Ala–Asp–aldehyde (YVAD-CHO), at the same concentration as
DEVD-CHO, and caspase-1 was not activated at all by the treatment of AH66 cells with both DXR and GSH–DXR. These results demonstrate
that DXR and GSH–DXR induce apoptotic DNA fragmentation via caspase-3 activation, but not via caspase-1 activation, and that GSH–DXR
enhances the activation of caspase-3 approximately 100-fold more than DXR. Moreover, the findings suggested that an upstream apoptotic
signal that can activate caspase-3 is induced within 6 h by treating AH66 cells with the drug.
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GSH–DXR was prepared as described previously (Asakura et al,
1997a). In brief, 1 mg of GSH and 0.5 mg of DXR in 0.5 ml of
0.15 M sodium chloride (NaCl) containing 0.1% glutaraldehyde
were incubated at room temperature for 30 min. After incubation,
GSH–DXR was separated from GSH and DXR using Dowex
50Wx8 (H1 form, 5 3 15 mm). The concentration of DXR was
measured by absorbance at 495 nm.
Preparation of cell extract
After treatment of AH66 cells with DXR or GSH–DXR, harvested
cells were washed with ice-cold 0.15 M NaCl and lysed with
ice-cold 0.5% Triton X-100 containing 10 mM Tris–HCl (pH 8.0)
and 10 mM EDTA. The cell lysate was spun down at 10 000 g for
10 min and the supernatant was used for the assays of DNA
fragmentation and caspase activity.
DNA fragmentation assay
After treatment of the cells (2 3 106) with DXR or GSH–DXR in
the presence or absence of a caspase family inhibitor, the cell
extract containing fragmented DNA was incubated with 0.5 mg
ml21 RNase A at 378C for 60 min, then with 0.5 mg ml21
proteinase K at 378C for 60 min. After incubation, fragmented
DNA precipitated by isopropanol was dissolved with 10 mM
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Figure 1 Induction of DNA fragmentation (A, C) and enhancement of caspase-3 proteolytic activity (B, D) in AH66 cells treated with DXR or GSH-DXR. (A, B)
The continuous treatment of the cells with 3 mM DXR (l l) or 0.1 mM GSH–DXR (•) for various periods of time. (C, D) The continuous treatment of AH66 cells with
various concentrations of DXR (l l) or GSH–DXR (•) for 24 h. Results are means 6 s.d. (three independent experiments)Tris–HCl (pH 8.0), 1 mM EDTA, 5% glycerol and 0.05%
bromophenol blue. The DNA fragments, separated by 2% agarose
gel electrophoresis, were stained with ethidium bromide, and
photographed on a UV transilluminator. The 123 base pair DNA
ladder (Gibco, BRL, NY, USA) was used as the standard
DNA fragments.
Assay of caspase-3 activity
Reaction mixtures, which contained 100 mM of DEVD-MCA,
the appropriate protein concentration of cell extract, 50 mM
HEPES–NaOH (pH 7.5), 10% glycerol and 2 mM dithiothreitol
with or without 0.1 mM DEVD-CHO, were monitored for AMC
liberation at 378C for 15 min in a spectrofluorometer at an excita-
tion wavelength of 380 nm and an emission wavelength of 460 nm
(Nicholson et al, 1995). The caspase-3 proteolytic activity was
expressed as the difference between nmol AMC liberations in
the presence and absence of the inhibitor per min per mg
protein. When the activity of caspase-1 was assayed, 20 mM
YVAD-MCA and 0.1 mM YVAD-CHO were substituted for
100 mM DEVD-MCA and 0.1 mM DEVD-CHO in the reaction
mixture respectively.
Protein determination
Protein concentration was assayed by a Bio-Rad protein assay kit
(Bio-Rad Lab., Tokyo, Japan) using BSA as the standard.
RESULTS AND DISCUSSION
Induction of apoptosis by GSH–DXR
When AH66 cells were continuously exposed to 3 mM DXR or
0.1 mM GSH–DXR for 24 h, the cell viability determined with a
colourimetric assay (Ohkawa et al 1993; Asakura et al, 1997a,
1997b), was decreased to approximately 50% compared with the
non-treated cells (data not shown). Inter-nucleosomal DNA frag-
mentation, a biochemical feature of the apoptotic process, was
observed in the cells treated with the drugs. DNA fragmentation
occurred within 15 h after continuous treatment with 3 mM DXR or
0.1 mM GSH–DXR (Figure 1A), and concentrations of DXR and
GSH–DXR as low as 1.0 and 0.01 mM, respectively, were found to
induce DNA fragmentation at 24 h of incubation (Figure 1C). This
result indicates that GSH–DXR is a potent inducer of apoptosis as
compared with DXR. In our recent report (Asakura et al, 1997b),
the cytotoxicity of GSH–DXR in AH66 cells was 170-fold higher
than that of DXR. Therefore, the extent of cytotoxicity for DXR
and GSH–DXR corresponded to the magnitude of apoptosis
induced by treatment with these drugs. Moreover, GSH–DXR
showed approximately tenfold more cytotoxic activity than
other large molecular weight derivatives of DXR, such as DXR
conjugated with BSA or with oxidized glutathione against AH66
cells (Asakura et al, 1997a). On the other hand, cytotoxicities of
DXR coupled to several small peptides, such as glycylglycine
and glycylglycylglycine, demonstrated almost the same cytotoxic
activity as DXR (Asakura et al, 1997a). The magnitude of
apoptosis induced by treatment with these conjugates also
corresponded to the extent of cytotoxicity for these drugs (data
not shown).
Inhibition of apoptosis by caspase inhibitor
In order to determine the kind of proteases involved in the
apoptotic process, the effects of two cysteine protease inhibitors,
YVAD-CHO (Thornberry et al, 1992) and DEVD-CHO
(Nicholson et al, 1995), on the apoptosis of AH66 cells were deter-
mined. As shown in Figure 2A, DEVD-CHO strongly inhibited
drug-induced DNA fragmentation in a dose-dependent manner,
and 10 mM of the inhibitor completely blocked DNA fragmenta-
tion. By contrast, YVAD-CHO (10 mM) did not exhibit any
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Figure 2 Prevention of drug-induced apoptosis by caspase inhibitor. AH66 cells were treated with 3 mM DXR or 0.1 mM GSH–DXR, and DEVD-CHO (0.1, 1 or
10 mM) or 10 mM YVAD-CHO, simultanously for 24 h. (A) DNA fragmentation. (B) Caspase-3 activity in the cells treated with inhibitor. Results are means 6 s.d.
(three independent experiments)protective effect on drug-induced apoptosis. This result suggests
that DXR- and GSH–DXR-induced DNA fragmentation occur via
activation of caspase-3, but not of caspase-1. Several reports have
described that anthracycline was able to induce inter-nucleosomal
DNA fragmentation in treated cells (Kaufmann et al, 1993;
Bose et al, 1995; Yamashita et al, 1995; Chen et al, 1996;
Mizushima et al, 1996), but the magnitude of the process induced
by GSH–DXR treatment was markedly more potent than that
induced by DXR.
Activation of caspase-3 by treatment with GSH–DXR
When AH66 cells were treated continuously with 3 mM DXR or
0.1 mM GSH–DXR, caspase-3 proteolytic activity in the cells did
not increase until 9 h, and increased linearly thereafter to a level
approximately 20- or 50-fold higher than that of the non-treated
control by 24 h respectively (Figure 1B). By treating with a higher
concentration of the drugs (100 mM DXR or 10 mM GSH–DXR),
enhancement of caspase-3 activity was not observed until 9 h (data
not shown). Therefore, caspase-3 was not activated until 9 h after
treatment with the drugs independent of the drug concentration.
These drugs increased caspase-3 activity in a dose-dependent
manner (Figure 1D). However, caspase-1 proteolytic activity was
not increased in cells treated with DXR or GSH–DXR in any time
period (data not shown). This result suggests that GSH–DXR
enhances the activity of caspase-3 about 100-fold more than
DXR-induced activation and the magnitude of the activation
induced by treatment with the drugs correlates with the extent of
DNA fragmentation.
When AH66 cells were treated simultaneously with DEVD-
CHO and the drug (3 mM DXR or 0.1 mM GSH–DXR) for 24 h,
cellular caspase-3 activity failed to increase (Figure 2B). However,
YVAD-CHO (10 mM) did not affect drug-induced activation of
caspase-3. It has been reported that active caspase-3 is generated
from its inactive precursor form by other active caspases via Fas
(Enari et al, 1996). Therefore, this result suggests that caspase-1
does not participate in proteolytic activation of caspase-3 in drug-
induced apoptosis.
DEVD-CHO prevents drug-induced apoptosis pathway
To examine whether or not DEVD-CHO could inhibit the initial
DXR- or GSH–DXR-induced DNA damage or the apoptotic
signal pathway itself, the cells were co-treated with the drug and
DEVD-CHO in various time schedules (Figure 3). When the cells
were treated with DXR or GSH–DXR for 6 h, DNA fragmentation
was induced 24 h after the treatment with the drug. It was demon-
strated that treatment of AH66 cells with the drug for 6 h was
enough to commit the cells to apoptosis (Figure 3, lanes 2 and 6).
Although the apoptotic signal was induced by 6-h treatment with
DXR and GSH–DXR, caspase-3 activation and DNA fragmenta-
tion occurred 12 h and 15 h after treatment respectively (Figure 1
A,B). On the other hand, after treating AH66 cells for 6 h with
DXR or GSH–DXR, the addition of 10 mM DEVD-CHO blocked
both DNA fragmentation and caspase-3 activation for as long as
24 h (Figure 3, lanes 3 and 8). However, when DEVD-CHO was
washed out 12 h after the treatment with the drug, apoptotic DNA
degradation occurred 12 h after the wash-out (Figure 3, lanes 5
and 9). This result suggests that DEVD-CHO can inhibit the
following apoptotic signal pathway, but does not affect the initial
drug-induced DNA damage in AH66 cells. By washing out the
inhibitor, caspase-3 activity in the cells was increased as compared
with that in the non-treated cells (5.1 to 72.5 pmol mg21 min21).
These results indicate that DEVD-CHO does not cause the
GSH–DXR-induced apoptotic signal to disappear, but the signal
for caspase-3 activation is temporarily suppressed. Moreover, the
findings suggested that an upstream apoptotic signal able to acti-
vate caspase-3 was already induced by treatment of AH66 cells
with DXR or GSH–DXR for 6 h.
GSH–DXR was synthesized by the conjugation between both
amino groups of DXR and of GSH via glutaraldehyde. Since the
SH group of GSH–DXR determined by fluorescent method using
o-phthalaldehyde showed the same concentration as DXR, it was
demonstrated that the SH group of GSH was present (data not
shown). In our recent reports (Asakura et al., 1997a, 1997b), the
SH group on the cysteine of GSH–DXR was important for
enhancement of the cytotoxicity, and GSH–DXR inhibited potent
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Figure 3 Prevention of drug-induced DNA fragmentation by delayed treatment of AH66 cells with DEVD-CHO (10 mM) as shown in treatment schedule.
Treatment of AH66 cells with 3 mM DXR or 0.1 mM GSH–DXR. M, 123 base pair DNA ladderGST activity but DXR did not. On the other hand, it has been
proposed that activation of other caspases, or release of granzyme-
like substance from granules (Darmon et al, 1995) or cytochrome c
from mitochondrial intermembrane (Kluck et al, 1997), or
ceramide generation (Bose et al, 1995; Mizushima et al, 1996)
induce activation of caspase-3 in cells. It has been reported
recently that ceramide links cellular stress responses induced by
anticancer drugs, such as DXR, to the CD95 (Apo-1/Fas) pathway
of apoptosis in human acute T-cell leukaemia CEM and Jurkat-16
cells (Herr et al, 1997). However, ceramide generation failed to
increase in AH66 cells treated with DXR or GSH–DXR in any
time period (data not shown). Drug-induced apoptosis in AH66
cells may not be linked to the Fas-mediated pathway.
Further work will attempt to identify the specific signalling
molecule and the transducing mechanism that play a role in
GSH–DXR-induced apoptosis in AH66 cells.
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